Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415480 | 0.85 | LTB4R (0.56) | NPC1RAB9ALTB4RLTB4R2ALOX5 | |
| SCHEMBL1516137 | 0.84 | NPC1 (0.75) | NPC1RAB9AKMT2ACA12CA9 | |
| SCHEMBL24835272 | 0.83 | ALDH1A1 (0.55) | KMT2A | |
| SCHEMBL5294174 | 0.82 | AKR1B1 (0.54) | NPC1RAB9ALTB4RLTB4R2ALOX5 | |
| SCHEMBL24835513 | 0.82 | LTB4R (0.49) | NPC1RAB9ALTB4RLTB4R2KMT2A | |
| SCHEMBL195224 | 0.82 | LMNA (0.58) | NPC1RAB9ACES2CES1AKR1B1 | |
| SCHEMBL339507 | 0.81 | CES2 (0.56) | NPC1RAB9ALTB4RLTB4R2ALOX5 | |
| SCHEMBL14415483 | 0.81 | TDP1 (0.62) | RAB9AKMT2ALMNARIPK1 | |
| SCHEMBL9122526 | 0.81 | LTB4R (0.56) | NPC1RAB9ALTB4RLTB4R2ALOX5 | |
| SCHEMBL5144362 | 0.79 | LTB4R (0.55) | NPC1RAB9ALTB4RLTB4R2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11050026-B2 | Spiro compound and organic light-emitting element comprising same | LG CHEM, LTD. | 2021-06-29 | — | — | US | disclosed |
| US-20180175304-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-06-21 | — | — | US | disclosed |
| EP-2141154-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11 -HYDROXYSTEROID DEHYDROGENASE TYPE I | Institute Of Medicinal Molecular Design, Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-5750531-A | ANTISECRETORY AGENTS FOR THE TREATMENT OF PEPTIC ULCER | YUHAN CORPORATION (KR) | 1998-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180175304-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | NR2E3, CRY1, ERG | NPC1 2121/4885RAB9A 2464/4885LTB4R 2541/4885 |
| US-11050026-B2 | Spiro compound and organic light-emitting element comprising same | NR2E3, CRY1, ERG | NPC1 2121/4885RAB9A 2464/4885LTB4R 2541/4885 |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | NPC1 203/4885RAB9A 2604/4885LTB4R 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.